Nemaura Medical Appoints The Ruth Group as Investor and Public Relations Counsel
29 March 2018 - 2:05AM
Business Wire
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology
company developing the wireless sugarBEAT® non-invasive glucose
monitoring system for adjunctive use by persons with diabetes,
today announced that it has appointed The Ruth Group (TRG), a
leading healthcare-focused strategic communications firm, to lead
its investor and public relations initiatives in the United States
and help build awareness of the Company’s sugarBEAT® non-invasive
continuous glucose monitoring (CGM) platform.
“With a number of key milestones coming up, including CE
Marking, the European commercial launch and initiation of our FDA
Clinical Program, we have decided it is the right time to more
proactively engage with the investment community and other key
audiences, and we are confident that The Ruth Group is the ideal
partner to support these efforts,” said Dr. Faz Chowdhury, Chief
Executive Officer of Nemaura. “We look forward to working with the
TRG team as we continue advancing toward our goal of bringing
sugarBEAT to market.”
“We are very pleased and excited to partner with such a dynamic
company as Nemaura. They have an exciting story and compelling
value proposition based around the novel sugarBEAT platform, and I
believe that the Company will benefit greatly from increased
investor and media awareness,” added Carol Ruth, Founder and
President of The Ruth Group. “Our experience and expertise in
medical technology and diagnostics positions us well to add
immediate value to the Company’s communications efforts.”
About Nemaura Medical, Inc.
Nemaura Medical Inc. (NASDAQ: NMRD), is a medical technology
company developing sugarBEAT® as a non-invasive, affordable
and flexible glucose monitoring system for adjunctive use by
persons with diabetes. SugarBEAT® consists of a disposable
adhesive skin-patch connected to a rechargeable transmitter, with
an app displaying glucose readings. For more
information, please
visit www.NemauraMedical.com and www.SugarBEAT.com.
Cautionary Statement Regarding Forward Looking
Statements
The statements in this press release that are not historical
facts, and may constitute forward-looking statements that are based
on current expectations and are subject to risks and uncertainties
that could cause actual future results to differ materially from
those expressed or implied by such statements. Those risks and
uncertainties include, but are not limited to, risks related to
regulatory approvals and the success of Nemaura Medical’s ongoing
studies, including the safety and efficacy of Nemaura Medical’s
sugarBEAT® system, the failure of future development and
preliminary marketing efforts, Nemaura Medical’s ability to secure
additional commercial partnering arrangements, risks and
uncertainties relating to Nemaura Medical and its partners’ ability
to develop, market and sell sugarBEAT®, the availability of
substantial additional equity or debt capital to support its
research, development and product commercialization activities, and
the success of its research, development, regulatory approval,
marketing and distribution plans and strategies, including those
plans and strategies related to sugarBEAT®. These and other risks
and uncertainties are identified and described in more detail in
Nemaura Medical’s filings with the Securities and Exchange
Commission, including, without limitation, its Annual Report on
Form 10-K for the current year, its Quarterly Reports on Form 10-Q,
and its Current Reports on Form 8-K. Nemaura Medical undertakes no
obligation to publicly update or revise any forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180328005752/en/
Nemaura MedicalBashir TimolDirector of Strategy &
Corporate Developmentbashir.timol@nemauramedical.comorThe Ruth
GroupLee Roth646-536-7012lroth@theruthgroup.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2024 to May 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From May 2023 to May 2024